Santen Corporate (EN)

2025 Press Release

RSS

Press Release

Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
Santen Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea
Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
Santen Launches Global Employee Volunteer Initiative on World Sight Day — Responding to 167 Calls from Visually Impaired Individuals in 26 Languages via the Be My Eyes App —
Santen and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China
Santen Publishes its Annual Integrated Report “Santen Report 2025”
Notice of Corporate Officer Changes
Santen Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension
Santen Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension
Santen Announces New Licensing Agreement with RemeGen for RC28-E Intravitreal Injection, an Anti-VEGF/FGF Dual-Target Fusion Protein
Santen Applies for Manufacturing and Marketing Approval in Japan for STN1013900 (netarsudil mesylate), Treatment for Glaucoma and Ocular Hypertension
Santen Launches Ryjunea® in Germany for the Treatment of Pediatric Myopia
European Commission Approves Santen’s Ryjunea® to Slow Progression of Paediatric Myopia
Santen Announces FY2025-2029 Medium-Term Management Plan
Santen and Bayer Yakuhin Launch New Pre-Filled Syringe for EYLEA® 8 mg, EYLEA® 8 mg intraocular injection kit 114.3 mg/mL
Notice of Board of Director and Corporate Auditor Nominations
Santen Announces China NMPA Approval of Tapcom🄬 in Patients with Open-Angle Glaucoma or Ocular Hypertension
Santen Receives Positive CHMP Opinion in Europe for Ryjunea🄬 for slowing the progression of paediatric myopia
Santen Receives Excellence Award at NIKKEI Integrated Report Award 2024
Santen launches RYJUSEA🄬 Mini ophthalmic solution 0.025% Japan’s first ophthalmic solution for slowing myopia progression
Santen launches Rocklatan🄬 ophthalmic solution (netarsudil 0.02% and latanoprost 0.005%), in Singapore for the treatment of patients with open-angle glaucoma or ocular hypertension
Notice of Corporate Officer Changes
Disease Awareness Activities During World Glaucoma Week (March 9-15) Will Highlight Importance of Early Detection and Treatment ～Helping to Promote Glaucoma Awareness Worldwide～